Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:05 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Losartan Use to Mitigate Arthrofibrosis Following Total Join Arthroplasty
NCT05157464 · NYU Langone Health · PHASE4 · withdrawn · last registry update 2023-12-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was not initiated, no participants enrolled.” | – | Registry record, NYU Langone Health |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AGTR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-11-12Results posted on the registry: Vicore Pharma AB, C21 (NCT05831644)
- 2024-10-17Phase 3 first posted: Hyundai Pharm, Ezetimibe/Rosuvastatin/Candesartan/Amlodipine + Candesartan/Amlodipine (NCT06646354)
- 2024-09-27Results posted on the registry: Pfizer, losartan + dextromethorphan (NCT03864042)
- 2024-09-26Phase 3 first posted: Universität Münster, Angiotensin II + Noradrenalin (NCT06615102)
- 2024-09-23Phase 3 first posted: Eurofarma Laboratorios S.A., N0877 + Benicar HCT ® Tablets 40 mg/25 mg (NCT06608472)
- 2024-09-23Also stopped (withdrawn): NYU Langone Health, Losartan (NCT06333522)
- 2024-09-04Results posted on the registry: Alexander Flannery, Angiotensin II (NCT04558359)
- 2024-08-15Also stopped (terminated): Organon and Co, MK0954, losartan potassium / Duration of Treatment - 12 weeks (NCT00449111)
- 2024-08-02Results posted on the registry: University of Kansas Medical Center, Losartan (NCT04335123)
- 2024-07-16Results posted on the registry: University of Wisconsin, Madison, Anti-Hypertensive (NCT05479097)
- 2024-07-03Results posted on the registry: Travere Therapeutics, Inc., sparsentan + irbesartan (NCT03762850)
- 2024-06-24Also stopped (terminated): Assistance Publique Hopitaux De Marseille, Losartan 50 mg and Spironolactone 25 mg pillules oral use (NCT04643691)
- 2024-06-18Also stopped (terminated): Organon and Co, hydrochlorothiazide (+) losartan potassium + losartan potassium (NCT00447603)
- 2024-06-10Also stopped (terminated): Amy Arnold, Angiotensin-(1-7) + Saline (NCT03604289)
- 2024-05-03Also stopped (terminated): Milton S. Hershey Medical Center, Angiotensin 1-7 + Saline (NCT03240068)
- 2024-05-02Results posted on the registry: James J. Irrgang, Losartan + Placebo (NCT02263729)
- 2024-05-02Also stopped (terminated): James J. Irrgang, Losartan + Placebo (NCT02263729)
- 2024-04-30Results posted on the registry: Travere Therapeutics, Inc., sparsentan + Irbesartan (NCT03493685)
- 2024-04-12Results posted on the registry: George Washington University, Angiotensin II (NCT01393782)
- 2024-04-08Phase 3 first posted: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Angiotensin II Injection + 0.9% sodium chloride injection (NCT06351150)
- 2024-04-03Also stopped (terminated): University of Alabama at Birmingham, Losartan + Losartan (NCT02373241)
- 2024-03-15Also stopped (withdrawn): University of New Mexico, Angiotensin II + Vasopressin (NCT05193370)
- 2024-03-06Also stopped (withdrawn): University of California, Los Angeles, Angiotensin II + Midodrine (NCT04048707)
- 2024-03-04Also stopped (terminated): OHSU Knight Cancer Institute, Abemaciclib + Abiraterone (NCT03878524)
- 2024-02-20Also stopped (terminated): Istituto Auxologico Italiano, enalapril tablets + placebo tablets (NCT00456963)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision